Highlights Odyssey Health, Inc.

Equities

ODYY

US67612C1027

Delayed OTC Markets Other stock markets 10:10:15 31/05/2024 pm IST			5-day change	1st Jan Change
0.0303 ^USD	-14.65%		-24.25%	-69.70%

22/03	Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
2023	Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	23/03	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	28/12	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	16/12	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	31/23/31	CI
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	05/23/05	CI
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23/23/23	CI
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	28/23/28	CI
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	15/23/15	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	18/23/18	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	18/23/18	CI
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	12/23/12	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	15/22/15	CI
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development	23/22/23	CI
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device	01/22/01	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	01/22/01	CI
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases	11/22/11	CI
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug	28/22/28	CI
Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II	13/22/13	CI
Odyssey Health, Inc. Announces the Successful Completion of Safety Measures for Their Phase I Multi-Day Ascending Dosing Clinical Trial	18/22/18	CI
Odyssey Health, Inc. Announces Positive Results from its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion	10/22/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Odyssey Health, Inc.

Equities

ODYY

US67612C1027

Highlights

Filters